Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07203625

Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

Led by Xuanwu Hospital, Beijing · Updated on 2026-03-19

316

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.

CONDITIONS

Official Title

Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 6518 years
  • Symptoms of posterior circulation ischemic stroke due to basilar artery occlusion
  • Basilar artery occlusion confirmed by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA)
  • Time from symptom onset to randomization within 4.5 to 24 hours
  • National Institute of Health Stroke Scale (NIHSS) score of 6 or higher prior to randomization
  • Functionally independent (modified Rankin Scale 0-2) before stroke onset
  • Intended for transfer for thrombectomy (patient or physician transfer)
  • Written informed consent from patient or legally authorized representative
Not Eligible

You will not qualify if you...

  • Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) less than 6
  • Evidence of intracranial hemorrhage or tumor (except small meningioma) on CT/MR
  • Complete cerebellar infarct with significant mass effect and compression of the 4th ventricle
  • Bilateral extensive brainstem infarction on imaging
  • Simultaneous occlusion of both anterior and posterior circulation (unless anterior occlusion >3 months ago)
  • Thrombolytic treatment within last 72 hours or intent to receive intravenous thrombolysis
  • Known allergy to tenecteplase ingredients
  • Other contraindications to intravenous thrombolysis except timing
  • Known bleeding disorders or anticoagulant use with elevated INR or recent use
  • Ischemic stroke or myocardial infarction in past 3 months
  • Previous intracranial hemorrhage or active internal bleeding in past 3 months
  • Severe uncontrolled hypertension (systolic >185 mmHg or diastolic >110 mmHg)
  • Baseline blood glucose below 50 mg/dl or above 400 mg/dl
  • Baseline platelet count below 100,000/bcL
  • Undergoing dialysis or severe renal insufficiency
  • Severe life-threatening allergy to contrast agents
  • Acute stroke within 48 hours after major cardiac, cerebrovascular interventions or surgery
  • Known or suspected cerebral vasculitis or endocarditis
  • Pregnancy or lactation
  • Serious advanced or terminal illness with life expectancy less than 6 months
  • Current participation in another investigational study
  • Any condition judged inappropriate for participation by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xuanwu Hospital, Capital Medical University

Beijing, China

Actively Recruiting

Loading map...

Research Team

J

Junwei Hao, MD

CONTACT

G

Gaoting Ma, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here